{"filing":{"accession_number":"0001628280-26-040812","cik":"0001048477","ticker":"BMRN","company_name":"BIOMARIN PHARMACEUTICAL INC","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"bmrn-20260602.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026040812/bmrn-20260602.htm"},"events":[{"id":6970,"run_id":6111,"accession_number":"0001628280-26-040812","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"BioMarin held its Annual Meeting of stockholders on June 4, 2026, with stockholders voting on four proposals: election of ten directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2017 Equity Incentive Plan increasing the share reserve by 7,650,000 shares. All four proposals passed with detailed vote tallies disclosed.","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4525,"accession_number":"0001628280-26-040812","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2017 Equity Incentive Plan increasing the share reserve by 7,650,000 shares. This is a material compensatory arrangement affecting the equity incentive framework available to directors and officers. The amendment became effective immediately upon stockholder approval at the June 2, 2026 Annual Meeting, making it a significant governance and compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:25:28.578774+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4526,"accession_number":"0001628280-26-040812","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of BioMarin's Annual Meeting of stockholders held on June 4, 2026, with voting outcomes on four proposals: election of ten directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2017 Equity Incentive Plan. The filing presents detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, confirming all four proposals passed. This is a quintessential shareholder_vote_results disclosure under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:25:28.578774+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4525,"accession_number":"0001628280-26-040812","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2017 Equity Incentive Plan increasing the share reserve by 7,650,000 shares. This is a material compensatory arrangement affecting the equity incentive framework available to directors and officers. The amendment became effective immediately upon stockholder approval at the June 2, 2026 Annual Meeting, making it a significant governance and compensation event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:25:28.578774+00:00","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-06-04"},{"id":4526,"accession_number":"0001628280-26-040812","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 filing discloses the results of BioMarin's Annual Meeting of stockholders held on June 4, 2026, with voting outcomes on four proposals: election of ten directors, ratification of KPMG LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2017 Equity Incentive Plan. The filing presents detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, confirming all four proposals passed. This is a quintessential shareholder_vote_results disclosure under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:25:28.578774+00:00","company_name":"BIOMARIN PHARMACEUTICAL INC","ticker":"BMRN","filing_date":"2026-06-04"}]}